Publications found:
73,128
Sort by:
2012 Global Heparin Market Outlook: Test Volume Forecasts by Country and Market Segment
US$ 3,080.00
... testing closer to the patient, creating additional opportunities and challenges for suppliers.This report presents a detailed analysis of the Heparin testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5- ...
April 2012
200 pages
INCYTE: Cheers for INCY - JAKAVI Receives CHMP Nod!
US$ 90.00
Incyte/ Novartis’ JAKAVI (ruxolitinib, JAK 1/2 inhibitor, Registered for MF; PhII ... triggers $40m milestone payment from Novartis (Ex-US rights), and INCY will received a second payment of $60m upon an achievement ... our report released on April 20, 2012 on INCY, titled “Cheers for INCY - JAKAVI Receives CHMP Nod!”
April 2012
2 pages
Power Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018
US$ 3,700.00
... to Susan Eustis, lead author of the study, 'Reimbursement drives power wheelchair markets'. As people and governments pay for medical insurance more money ... , permitting the patient to control mobility for the rehabilitation efforts. Power wheel chairs give patients the ability to control movement. Transport ...
April 2012
467 pages
REGENERON: Tapping Other TRAPS in 3Q12 - ZALTRAP and ARCALYST!
US$ 90.00
... with Bayer for Ex-US, wet AMD) launch skyrocketed Regeneron (REGN); we expect other TRAP based products in the pipeline to sustain this ... Sanofi granted A Priority Review for ZALTRAP (VEGF trap/ aflibercept, R, mCRC – 2nd-line; PhII/ ... 5, 2012 on REGN, titled “Tapping Other TRAPS in 3Q12 - ZALTRAP and ARCALYST!”
April 2012
5 pages
Global Home Healthcare Device Industry 2012 - 2017: Trend, Profit, and Forecast Analysis
US$ 1,980.00
... the face of global home healthcare device industry. Lucintel’s study provides a concise overview of the global home healthcare device industry. The report tracks four regions of global home healthcare device industry. This study ... ) for global home healthcare device industry analysis Gross and net profit trends in the global home healthcare device industry analysis Cost structure trend in the global as well as regional home healthcare device industry ...
April 2012
-
UAE Healthcare Sector Forecast to 2014
US$ 1,200.00
In the past few years, the UAE healthcare industry has shown an unprecedented growth which is expected to continue in the future due to increasing population, rising prevalence of lifestyle diseases a...
April 2012
135 pages
Saudi Arabian Healthcare Forecast to 2015
US$ 1,000.00
Saudi Arabia represents the largest healthcare market in the GCC region that possesses a huge potential for further expansion due to rising healthcare needs. The government and health regulatory autho...
April 2012
115 pages
G-Protein Coupled Receptors (GPCRs): Market Research Report
US$ 4,500.00
This report analyzes the Global market for G-Protein Coupled Receptors (GPCRs) in US$ Billion. Annual estimates and forecasts are provided for ... through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 43 companies including 7TM Pharma A/S, Actelion Pharmaceuticals ...
April 2012
299 pages
Global RNAi Market Analysis
US$ 1,200.00
RNA Interference (RNAi) has emerged as a breakthrough in the life sciences industry. It presents an extensive potential in multiple areas, such as drug discovery, drug development, and therapeutic app...
April 2012
105 pages
Herpes Simplex Virus Treatment: Market Research Report
US$ 4,600.00
This report analyzes the worldwide markets for Herpes Simplex Virus Treatment in US$ Million. The report provides separate comprehensive analytics for the US, ... , Inc., Novartis International AG, Sanofi, Starpharma Holdings Limited, and Vical. Market data and analytics are derived from primary and secondary ...
April 2012
300 pages
Global Protein Therapeutics Market Forecast to 2015
US$ 1,800.00
Protein-based therapies have found a prominent place in the biopharmaceutical industry since the launch of human insulin product. They have become one of the most effective clinical methods to treat w...
April 2012
160 pages
Therapy Trends: Multiple Sclerosis
US$ 4,995.00
An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse futu...
April 2012
160 pages
Market Access: Communicating Value Stories to Payers
US$ 595.00
... affiliate organisations. What strategies are emerging to tackle these challenges? Market Access: Communicating Value Stories to Payers shares up-to-the-minute insights and case studies from ... finding their way through this new environment. Report Overview Market Access: Communicating Value Stories to Payers provides unique, practical insights into how companies can ...
April 2012
46 pages
Roche - GSK - EMILIA: TDM1 ready to take over Tykerb
US$ 90.00
Today, Roche and ImmunoGen announced the topline data from EMILIA study ... T-DMI in this indication and this should come at the expense of GSK’s Tykerb, which is the current standard of care in this setting. This ...
March 2012
3 pages
Merck - IMPROVE IT update - Appears trending favorably
US$ 90.00
Today, Merck announced that the Data Safety Monitoring Board has given a go-ahead signal to the IMPROVE-IT after it conducted a pre-specified second interim ... . The company has also indicated that the projected completion of IMPROVE IT by 2013 may change.
March 2012
1 pages
Galapagos - Partnership Impact Sustainable?
US$ 140.00
Though deal with Abbott has added credibility to Galapagos’ GLPG0634 (PhII, an oral JAK1 inhibitor), there is still ... by 2014 could elevate GLPG, but our analysis of the impact of catalysts for 2012-13 suggest that …. GLPG0634 will be ... report released on 6th March on GLPG titled “Partnership Impact Sustainable?”
March 2012
6 pages
JAPAN DOMESTIC PHARMA- Competitive Landscape of Leading Therapy Classes - UPDATE
US$ 600.00
In this updated issue of ‘Japan-Domestic Pharma Market Summary’ for 2012, we present major 10 Thx Class in Japan which covers ~40% of total Japan domestic pharma market (~¥8.0 trillion). This will ... breakthroughs in each class – which includes products from all pharma companies operating in Japan including MNCs.
March 2012
27 pages
ROCHE - CHUGAI, RoActemra monotherapy Superior to Humira: ADACTA Study
US$ 90.00
In a Ph IV ADACTA monotherapy study, RoActema has shown superior improvement ... the biologic RA market (~ $10B). The data should support Roche’s sNDA for 1st line approval in the US (submitted in December ... in EU where Actemra is already approved in first line, Roche will file for a label change based on this data.
March 2012
2 pages
Surgical Apparel Market in the United States
US$ 200.00
... even less than models of the past. The surgical apparel market in United States has plenty of competition but the field is narrowing ... analyzes the Surgical Apparel Market in the United States in a comprehensive report which covers the basics of the market including market profile, market statistics, analysis ...
March 2012
20 pages
Orthopedic Orthotics: Market Research Report
US$ 4,200.00
This report analyzes the worldwide markets for Orthopedic Orthotics in US$ Million by the following Product Segments: Orthopedic Braces (Knee Braces, Ankle Braces, & ... NV, Ossur hf., Restorative Care of America, Inc., and Zimmer Holdings, Inc. Market data and analytics are derived from primary and secondary ...
March 2012
291 pages
Orthopedic Prosthetics: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Orthopedic Prosthetics in US$ Million by the following Product Segments: Hip Prosthesis, Knee Prosthesis, and ... Aesculap Implant Systems, Inc., Biomet, Inc., Corin Group PLC, DePuy Orthopedics, Inc., MatOrtho™ Ltd., DJO Surgical, Exactech, Inc., Smith & Nephew Plc ...
March 2012
353 pages
Laboratory Chemical Reagents: Market Research Report
US$ 4,950.00
This report analyzes the worldwide markets for Laboratory Chemical Reagents in US$ Million by the following Product Segments: Molecular Biology (Monoclonal & Polyclonal ... Biotech, Sigma-Aldrich Corp., Takara Bio, Inc., Wako Pure Chemical Industries Ltd., and Waters Corp. Major Monoclonal and Polyclonal ...
March 2012
815 pages
Breath Analyzers: Market Research Report
US$ 4,500.00
This report analyzes the worldwide markets for Breath Analyzers in Thousands of US Dollars by the following End-Use Segments: Regulatory Authorities, Employee ... , Inc., PAS Systems International, Inc., Paladin Labs Inc., and Q3 Innovations, LLC. Market data and analytics are derived from primary and secondary ...
March 2012
162 pages
L-Carnitine: Market Research Report
US$ 4,200.00
This report analyzes the worldwide markets for L-Carnitine in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, ... Technology Development Co., Ltd., and Zhejiang Jiashan Chengda Pharm & Chem Co., Ltd. Market data and analytics are derived from primary and secondary ...
March 2012
209 pages
Indian Hospital Services Market Outlook
US$ 800.00
The hospital services’ market represents one of the most lucrative segments of the Indian healthcare industry. Various factors, such as increasing prevalence of diseases, improving affordability, and...
March 2012
100 pages
New Thinking in Patient Adherence
US$ 695.00
Patient non-adherence is estimated to represent $290 billion per year in avoidable medical expenses in the United States alone. Consumers’ motivations for non-compliance are complex; up to 80% of peop...
March 2012
62 pages
Bristol-Myers Squibb - Eliquis: FDA Decision Date Extended by Three Months
US$ 90.00
... BMY, the USFDA has extended the review period for Eliquis by 3 months (new PDUFA June 28th). At this ... has not announced any advisory committee to discuss Eliquis approval, but one may not rule out ... concerns over safety of Dabigatran. This delay in Eliquis approval, will obviously give some additional time for ...
February 2012
2 pages
GALAPAGOS - Santa Arrives – Late but With Bounty!
US$ 90.00
Today’s exclusive global agreement of Galapagos’ (GLPG) GLPG0634 (PhII, RA, oral JAK1 inhibitor) with a veteran player in ... , please read our report released on 29th February on GLPG titled “Santa Arrives – Late but With Bounty!”
February 2012
3 pages
DAIICHI SANKYO - Growth Story Remains Intact!
US$ 90.00
... rating on Daiichi Sankyo (DS) while revising down 12-months TP to ¥1,850 on account of incorporating likely impact of Ranbaxy settlement cost and tax reforms in Japan. Going forward ...
February 2012
2 pages
RANBAXY - Teva Partnership Hurts
US$ 140.00
... the unexpectedly high payment of ~$150m to Teva under the Lipitor generic agreement. Ranbaxy generated ~$300m from generic Lipitor that ... (1) Daiichi-Ranbaxy likely to become the largest generic company in Japan generics market (2) leveraging of Ranbaxy’s emerging market infrastructure (especially India) to ...
February 2012
6 pages
VIVUS: Potential for Adding More Weight in April
US$ 140.00
... safety profile. With the risk of generics, commercial potential of Avanafil worth... The upside could be more in case of a buyout, favorable licensing deal, ... approval time in April… For more details, please read our report released on February 24, 2012 on VVUS, titled “Potential for Adding More Weight in April”
February 2012
9 pages
REGENERON: Marching Towards Profitability!
US$ 140.00
... Lucentis)! REGN should finally evolve from a Rising Star to become a profitable Biotech from 2012 onwards on the strength of its pipeline and ... , please read our report released on February 17, 2012 on REGN, titled “Marching Towards Profitability!”
February 2012
8 pages
SUN PHARMA - Strong Base Business; Protonix Liability Not A Major Concern
US$ 140.00
We reiterate Sun Pharma as our Top Pick in the Indian pharma space after it’s higher ... to note that FY12 performance represents purely the base business with no one off upsides. Future growth ... new target price by applying a PE of 20x on FY13 base business earnings, valuing upcoming Para IVs at Rs. 25 per share ...
February 2012
6 pages
CIPLA, Withdrawing Positive Investment Alert - Structural Issues Loom Large
US$ 140.00
We withdraw our Positive Investment Alert post the dismal Q3 FY12 result that highlights Cipla’s structural issues. In addition, we believe that the supply of API of ... estimates by 18% and 12% in FY12 and FY13. We thus withdraw our Positive Investment Alert and reiterate our Market Perform rating with a target ...
February 2012
5 pages
VERTEX PHARMA - IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet!
US$ 140.00
... with G551D mutation), we see little risk to Vertex (VRTX) profitability for at least next three years ... of IL28B CC Genotype. Vertex has also accelerated the pace of developing IFN-free drugs to remain in the ... 14th Feb., 2012 on Vertex titled “IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet ...
February 2012
12 pages
